VCB-1203 / Vaxcell-Bio Therap - LARVOL DELTA

Baxel Bio announced on the 19th that it has completed the Japanese patent registration for 'VCB-1203', a CAR-T treatment targeting the immune checkpoint protein PD-L1. [Google translation] (HIT News) - "In addition, VCB-1203 confirmed the results of maintaining cancer cell killing power for a long time while reducing normal cytotoxicity in non-clinical trials. It is explained that the Japanese patent registration was made based on its characteristics in terms of efficacy, safety, and stability."

Patent • Preclinical • Colorectal Cancer • Gastric Cancer • Ovarian Cancer • Pancreatic Cancer